Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.2552W HIGH $7.44
Volume
4.08 M
Value Traded
6.11 M
Short % Float
13.87%
Days to Cover
1.5
+13.48%Week
+2.8%1 Month
-26.81%3 Month
-24.06%6 Month
-55.28%5 Year
-55.28%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
387.15 M
EPS (TTM)
-0.98
P/E Ratio
-
Ent. Value
199.50 M
Total Shares
95.83 M
Float Shares
50.62 M
Insiders
47.45%
Institutions
59.66%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ZURA Catalyst Timeline
Dated clinical, regulatory and corporate events for Zura Bio Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for Zura Bio Limited
169Total events
8Upcoming
24Tier-1 (high impact)
2022 to 2028Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Inducement grants of options for 250,200 Class A Ordinary Shares to five new employees
●R&D DayPresentation
Zura Bio to participate in Cantor Global Healthcare Conference fireside chat
◆Topline ReadoutTibulizumabClinical Data
Topline results for primary endpoint at Week 16 expected
hidradenitis suppurativasource ↗
▲Enrollment CompleteTibulizumabTrial
TibuSURE Phase 2 enrollment completed with 91 participants
systemic sclerosissource ↗
◆Trial CompletionTibulizumabTrial
Phase 2 study completion for tibulizumab in hidradenitis suppurativa
hidradenitis suppurativasource ↗
▲Enrollment CompleteTibulizumabTrial
Exceeded enrollment target in HS Phase 2 study
Hidradenitis Suppurativasource ↗
▲Enrollment CompleteTibulizumabTrial
TibuSHIELD Phase 2 enrollment completed with 247 participants
hidradenitis suppurativasource ↗
●Enrollment UpdateTibulizumabTrial
TibuSHIELD enrollment of ~225 patients on track
hidradenitis suppurativasource ↗
▲Enrollment CompleteTibulizumabTrial
TibuSHIELD enrollment complete in HS with 247 participants
hidradenitis suppurativasource ↗
●Poster PresentationTibulizumabPresentation
Poster presentation of TibuSURE Phase 2 study design at Systemic Sclerosis World Congress
systemic sclerosissource ↗
▼Equity OfferingCorporate
Closing of $144 million public offering and full exercise of underwriters' option
▼Equity OfferingCorporate
Pricing of $125 million public offering of Class A ordinary shares and pre-funded warrants
▼Equity OfferingCorporate
Proposed public offering of Class A ordinary shares and pre-funded warrants
◆Oral PresentationPresentation
Zura Bio participates in Guggenheim Emerging Outlook: Biotech Summit fireside chat
▼Equity OfferingCorporate
Closed underwritten public offering with gross proceeds of approximately $144 million
◆Management ChangeCorporate
Appointment of Sandeep Kulkarni, M.D. as CEO effective January 21, 2026
●Oral PresentationPresentation
Zura Bio to participate in fireside chat at Cantor Global Healthcare Conference
◆Management ChangeCorporate
Verender Badial steps down as CFO, remains non-executive employee through July 31, 2025
▲Trial InitiationTibulizumabTrial
First clinical site activated for TibuSHIELD Phase 2 study
hidradenitis suppurativasource ↗
◆Trial InitiationTibulizumabTrial
Expected entry into Phase 2 clinical development for hidradenitis suppurativa
hidradenitis suppurativasource ↗
◆Trial InitiationTrial
Anticipated launch of Phase 2 study for hidradenitis suppurativa in Q2 2025
hidradenitis suppurativasource ↗
◆Oral PresentationPresentation
Fireside chat at Leerink Partners Global Healthcare Conference
▲IND ClearanceTibulizumabIND
IND in effect to support Phase 2 trial in HS
hidradenitis suppurativasource ↗
◆Topline ReadoutianalumabClinical Data
Topline Data for VAY736 (ianalumab) from Phase 2 Platform Study in HS
hidradenitis suppurativasource ↗
◆IND SubmissionTibulizumabIND
IND submission for Phase 2 trial of tibulizumab in HS
hidradenitis suppurativa (HS)source ↗
◆Manufacturing MilestoneTibulizumabCMC / Inspection
Manufacturing initial phase 3 clinical supply in 2025
systemic sclerosissource ↗
Past FDA Catalysts and PDUFA Decisions
How ZURA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 63%
Micro Cap(rank 425 of 674)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tibulizumab Monoclonal antibodyNCT06993610 | Hidradenitis Suppurativa (HS) | Phase 2 | ACTIVE NOT_RECRUITING | 247 | Apr 1, 2027 | ||||||
| Tibulizumab Monoclonal antibodyNCT06843239 | Systemic Sclerosis (SSc) | Phase 2 | ACTIVE NOT_RECRUITING | 80 | Jan 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every ZURA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| remibrutinib | hidradenitis suppurativa | 2024-04-23 | 72.7; 48.5; 34.7; 38.0 (21.1 to 55.0); 13.8 (4.4 to 32.0); 72.3; 48.5; 34.9; 37.2 (19.7 to 53.0); 13.9 (4.2 to 31.9); 99.9; 89.6Read More | xA9;2024 Zura Bio Ltd. Nasdaq Ticker: ZURA Advancing clinical outcomes through pioneering dual-pathway biology April 2024 ©2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes  Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Nistala KiranOfficer (See Remarks) | Grant/Award | 340,900 340,900 held | $0.00 | 04/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ZURA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| VR Adviser, LLC | 1.2 % (-14.3 %) | 37.97 M | 6.43 M |
Ownership Trends
ZURA Short Interest
Shares sold short, counted twice a month.
13.87%
Short % of Float
of tradable shares sold short
7.0M
Shares Sold Short
-25.1% vs prior count
1.5 Low
Days to Cover
trading days of normal volume to buy every short share back
4.8M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ZURA ranks across every disease it competes in
Competitive Position is a premium feature
See how ZURA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialZURA News
ZURAZura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Limited announced the grant of inducement awards for options to purchase 250,200 Class A Ordinary Shares to five new employees. This grant, approved by the Compensation Committee, is part of their strategy to attract talent under Nasdaq Listing Rule 5635(c)(4). The options have a four-year vesting schedule.
Read more →ZURA▲ +19.9%on this newsshared move
Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio reported its third quarter 2026 financial results, highlighting successful enrollment in its TibuSHIELD and TibuSURE Phase 2 studies, exceeding participant targets. The company anticipates topline data from TibuSHIELD in Q4 2026 and TibuSURE in H1 2027. With $187.7 million in cash, Zura expects to fund operations through at least 2028.
Read more →ZURAZura Bio to Participate in the Cantor Global Healthcare Conference
Zura Bio Limited, a clinical-stage biotechnology company, will participate in the Cantor Global Healthcare Conference. The event is scheduled for September 9, 2026, in New York, NY. This participation underscores Zura's commitment to connecting with investors and discussing its innovative approaches to treating autoimmune and inflammatory diseases.
Read more →ZURAZura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio Limited announced its financial results for Q2 2026, highlighting significant progress in its tibulizumab programs. The company reported strong execution and enrollment advancements. Recent corporate updates suggest a positive trajectory for Zura as it continues to develop treatments for autoimmune and inflammatory diseases.
Read more →ZURA▲ +5.2%on this news
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
Zura Bio has successfully surpassed its enrollment targets for Phase 2 studies in Hidradenitis Suppurativa (HS) and Systemic Sclerosis (SSc). This achievement reflects the company's strong performance and commitment to advancing its Tibulizumab program. The expansion of this program highlights Zura Bio's strategic focus on addressing these challenging conditions.
Read more →ZURAZura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Limited has granted an inducement award of an option to purchase 600,000 Class A Ordinary Shares to Muzammil Mustufa, the new Chief Business Officer. This award, approved by the Compensation Committee, is part of the company's strategy to attract talent and is compliant with Nasdaq Listing Rule 5635(c)(4). The option has an exercise price of $4.80 per share and will vest over four years.
Read more →ZURAZura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
Zura Bio has announced the appointment of Muzammil Mustufa as Chief Business Officer. This expansion of the leadership team is aimed at enhancing the company's strategic direction and growth potential. Mustufa's experience is expected to contribute positively to Zura Bio's objectives.
Read more →ZURA▼ -7.2%on this news
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio Limited reported its financial results for Q1 2026, highlighting a strengthened balance sheet with $225.6 million in cash. The company is advancing two Phase 2 studies for its lead product, tibulizumab, with anticipated data readouts later this year and in 2027. Despite an increase in net loss and R&D expenses, Zura's leadership changes and ongoing clinical trials position it favorably in the market.
Read more →ZURA▼ -10.1%on this news
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
Zura Bio Limited reported its financial results for the year ending December 31, 2025, highlighting significant progress in its Phase 2 clinical programs. The company raised $144 million to strengthen its balance sheet and is focused on advancing its lead candidate, tibulizumab. Anticipated data readouts from ongoing studies are expected in late 2026 and early 2027, positioning Zura for potential growth despite increasing net losses.
Read more →ZURACorporate overview
Zura Bio Ltd. presents its innovative bispecific antibody, Tibulizumab, designed to target both BAFF and IL-17 signaling pathways. The company is advancing two independent Phase 2 trials, TibuSHIELD and TibuSURE, which focus on addressing the unmet medical needs in diseases related to systemic sclerosis, a complex autoimmune condition. Tibulizumab represents a novel approach in the treatment landscape, enabling potential expansions into other autoimmune diseases pending clinical validation.
Read more →ZURAZura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
Zura Bio announced that its Phase 2 TibuSURE study design will be presented at the Systemic Sclerosis World Congress in March 2026. The study evaluates tibulizumab, a bispecific antibody targeting IL-17A and BAFF, in adults with systemic sclerosis. The trial aims to enroll 80 participants and will assess the drug's efficacy and safety over 24 weeks, with results expected in 2027.
Read more →ZURAZura Bio to Participate in Upcoming Investor Conferences
Zura Bio Limited will participate in two upcoming investor conferences in Miami, FL. The management team will engage in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026, followed by investor meetings at the Jefferies Biotech on the Beach Summit on March 11, 2026. The company is focused on developing novel therapies for autoimmune and inflammatory diseases.
Read more →ZURAZura Bio to Participate in Upcoming March 2026 Investor Conferences
Zura Bio Limited, a clinical-stage biotechnology firm, announced its participation in upcoming investor conferences, including the Leerink Global Healthcare Conference and the Jefferies Biotech on the Beach Summit. The company's management will engage with investors to discuss its innovative pipeline, which focuses on treatments for autoimmune and inflammatory diseases. Zura's lead candidate, tibulizumab, is currently in Phase 2 studies.
Read more →ZURAZura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Zura Bio Limited has successfully closed a public offering of Class A ordinary shares and pre-funded warrants, raising approximately $144 million. The offering included 21.2 million shares priced at $6.25 each, along with additional shares sold due to underwriters' full exercise of their purchase option. This funding will support Zura's clinical-stage development of novel therapies for autoimmune and inflammatory diseases.
Read more →ZURAZura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
Zura Bio Limited has announced the pricing of its public offering of 18.2 million Class A ordinary shares at $6.25 each, aiming to raise $125 million. The offering includes pre-funded warrants for additional shares and is set to close on February 26, 2026, pending customary conditions. The funds will support Zura's clinical development of therapies for autoimmune diseases.
Read more →ZURAZura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
Zura Bio Limited announced a proposed public offering of Class A ordinary shares and pre-funded warrants. The offering aims to enhance its financial resources, which is crucial for its development of medications targeting autoimmune and inflammatory diseases. The company plans to provide underwriters an option to purchase additional shares, although the completion of the offering depends on market conditions and other uncertainties. Detailed prospectus information will be made available through regulatory filings.
Read more →ZURA▲ +5.3%on this newsshared move
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors
Zura Bio Limited has appointed Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. Both appointees bring significant experience in immunology and drug development, which will support Zura's Phase 2 programs and growth opportunities. Neil Graham will step down from the Board on the same date.
Read more →About Zura Bio Limited
Headquarters4225 EXECUTIVE SQUARE, LA JOLLA, CA, 92037
BIOPHARMAWATCH ELITE PLUS
Trade the next ZURA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime